MedTrace Logo

Acceptability of Long-term Progestin-only Contraception in Europe

NCT00931827 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 436

Last updated 2013-12-24

No results posted yet for this study

Summary

The study examines the use of Mirena or Implanon for long-term contraception in women. The duration of therapy use is the key focus of the study. Also, any reasons for discontinuation and the safety profile will be examined. In addition, patients are asked to fill out a short questionnaire about their menstrual bleeding before and during therapy.

Conditions

  • Contraception

Interventions

DRUG

Levonorgestrel IUS (Mirena, BAY86-5028)

Patients under daily life treatment receiving Mirena according to local drug information.

DRUG

Implanon (Etonogestrel)

Patients under daily life treatment receiving Implanon according to local drug information.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • France
  • Ireland
  • Slovakia
  • United Kingdom

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931827 on ClinicalTrials.gov